Desloratadine 5 mg once daily improves quality of life in chronic idiopathic urticaria

S. Seidenari, A. Cirillo, S. Amoroso, M. L. Flori, P. Amerio, E. Ricciuti, G. A. Vena, E. Berardesca, C. Le Grazie, F. Giusti, R. Capizzi, M. A. Marino, C. Barbera, M. Ferraro, A. Cristaudo, E. Di Lella, G. Borroni, M. Mosca, S. Calvieri, A. G. RighettaS. Chimenti, R. Barbati, A. Ciccarelli, C. Crosti, R. Calcaterra, E. Tolomio, O. De Pità, A. Provini, A. Finzi, P. Pigatto, M. Pellegrino, A. Molinu, A. Giomi, V. Griseta, A. Lerario, G. Leigheb, M. Bertero, R. Zuccoli, P. Lisi, L. Stingeni, K. Hansel, M. Lospalluti, M. L. Carriera, V. Serpenti, L. Muratore, A. Offidani, O. Simonetti, C. Simonini, C. Ortolani, J. W. Schroder, G. Vighi, F. Pezzuto, A. Pio, F. Ricciuti, L. Viola, P. Santoianni, G. Lembo, G. Moffa, E. Sbano, V. Altamura, Brindisi C. Troise, D. Bignardi, S. Voltolini, A. Tulli, A. De Benedetto, P. Toto, C. Varotti, T. Bianchi, G. A. Vena, N. Cassano, L. Zichichi, V. Maltese

Research output: Contribution to journalArticlepeer-review


Aim. Desloratadine (DL) is an effective treatment for chronic idiopathic urticaria (CIU) symptoms, but there is little information about its impact on patients' perceived general wellbeing. The primary objective was to measure the effect of DL on the quality of life (QoL) of CIU patients, using the Dermatology Life Quality Index (DLQI). Secondary objectives were: evaluation of the effects of DL on pruritus and number of hives, sleep and daily activities, overall CIU condition, and assessment of therapeutic response. Safety and tolerability of DL were also evaluated. Methods. Two-hundred and fifty-five patients, aged 18-79 years and with moderate to severe CIU, were treated with DL 5 mg once daily for 28 days. Patients recorded signs and symptoms scores daily, and completed the DLQI questionnaire at baseline and on treatment days 7, 14, 21 and 28. Patients and investigators jointly evaluated overall CIU condition and therapeutic response at days 14 and 28. Results. After 28 days of treatment, DL significantly reduced mean overall DLQI score from 9.4 (±5.4) at baseline to 3 (±4.1) (-66.1%; P

Original languageEnglish
Pages (from-to)207-214
Number of pages8
JournalGiornale Italiano di Dermatologia e Venereologia
Issue number3
Publication statusPublished - 2006


  • Antihistamines
  • Chronic idiopathic urticaria
  • Dermatology life quality index (DLQI)
  • Desloratadine
  • Quality of life

ASJC Scopus subject areas

  • Dermatology


Dive into the research topics of 'Desloratadine 5 mg once daily improves quality of life in chronic idiopathic urticaria'. Together they form a unique fingerprint.

Cite this